Medication info
Sitagliptin 50 mg (Sitagliptin Hydrochloride Monohydrate) Tablet

Sitagliptin 50 mg (Sitagliptin Hydrochloride Monohydrate) Tablet

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tablet
Manufacturer / importer
Shinpoong Pharmaceutical Co., Ltd.
Appearance
Bright yellow-orange round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202102483 · Approved 2021.03.22 · Insurance code 648508090

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For monotherapy or combination therapy, administer 100 mg once daily; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Shinpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used in combination with diet and exercise to enhance blood sugar control in patients with type 2 diabetes. It can be administered alone for those starting treatment for the first time, and if blood sugar is not adequately controlled with monotherapy, it is used in conjunction with metformin. Additionally, if blood sugar control is difficult with other diabetes medications such as sulfonylureas, metformin, thiazolidinediones, or insulin, this medication can be added. Even when using multiple medications, this drug can be used to enhance therapeutic effects if blood sugar control is insufficient. In summary, this medication plays an important role in aiding blood sugar control at various stages of diabetes treatment and can be used either alone or in combination based on the patient's condition to improve blood sugar management.

How to take

Adult dose

For monotherapy or combination therapy, administer 100 mg once daily; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication may cause serious allergic reactions after administration, so if symptoms such as rash or difficulty breathing occur, discontinue use immediately and consult a physician. There is also a risk of serious inflammation of the pancreas known as pancreatitis, so if symptoms like abdominal pain or vomiting arise, inform medical personnel promptly. This medication should not be used by patients with type 1 diabetes or diabetic ketoacidosis, nor in cases of hypersensitivity to this medication or its components. Patients with decreased renal function should have their dosage adjusted, hence regular renal function tests are necessary. During the course of this medication, hypoglycemic symptoms may occur, especially when taken with insulin or sulfonylureas, so blood sugar levels should be closely monitored. If severe joint pain or blisters on the skin occurs, notify a doctor immediately and discontinue the medication. Pregnant or nursing women are advised to avoid using this medication, and safety in children and adolescents under 18 years has not been established. Elderly individuals may have decreased renal function, so dosage adjustment and renal function testing is required. Be aware that interactions may occur when taken with other medications, so inform healthcare providers of any concurrent medications being taken. In the case of overdose, visit a hospital immediately for appropriate treatment, and this medication can be partially removed by dialysis.

Side effects

Anaphylaxis, angioedema, Stevens-Johnson syndrome, exfoliative dermatitis, acute pancreatitis, hypoglycemia, nasopharyngitis, upper respiratory tract infection, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, severe joint pain accompanied by disability, blistering pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevation of liver enzymes, acute renal failure, pneumonia, diabetes complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, elevated blood triglycerides, gastritis, weight loss, hypertension, hypernatremia, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture exposure and kept at room temperature between 1 and 30 degrees Celsius. Proper storage will maintain the medication's effectiveness and ensure safe use.

Appearance and packaging

Appearance

Bright yellow-orange round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.